In 2025, biopharma M&A activity reached about $70 billion in upfront payments through Oct. 10, with 17 deals worth $1 billion or more.1 Three megadeals account for half of the total: Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, Merck Verona for $10 billion, and Sanofi Blueprint Medicines for $9.1 billion.[1] The MASH and metabolic disease area attracted $8.3 billion, including the acquisitions of Novo Nordisk for $5.2 billion (Akero Therapeutics), Roche for $2.4 billion (89bio) and GSK for $1.2 billion.[1] The average number of deals in 2025 was 21, above the historical annual average of 19 over the past 15 years, with the value of deals already exceeding the 2024 total.2 The largest deal of the year, Johnson & Johnson's $14.6 billion deal, secured Caplyta for schizophrenia and bipolar depression with exclusivity through 2040.[1] In Q2 2025, there were 26 deals totaling $19.3 billion, with an average deal size of $1.4 billion.4 In Q3 2025, the value of deals increased 36.7% to $43.2 billion compared to the previous quarter.5